Our Pipeline

Our goal is to transform the prevention and treatment of cancers and infectious diseases to significantly improve the lives of patients by developing and commercializing a new class of immunotherapeutics.

We are leveraging our modular arenavirus platform to develop the following product candidates for multiple cancers and infectious diseases - the efficacy of our replicating and non-replicating platforms is being tested all across our pipeline:

Development Stage
Compound
Antigen
Target
Pre-ClinicalPre.
Phase 1Ph1.
Phase 2Ph2.
Phase 3Ph3.
Anticipated Milestones
Global Rights
HB-200
E6/E7
HPV16+* Cancer
Data update no later than 4Q 2021; RP2D in 4Q 2021
HB-201 (1)
Replicating
Single Vector LCMV
E6/E7
HPV16+* HNSCC 2L*
Phase 2 Start
Q1 2022
HB-201/HB-202 (1)
Replicating
Alternating 2-Vector
LCMV, PICV (2)
E6/E7
HPV16+* Anal 2L
Phase 2 Start
Q1 2022
HB-201/HB-202 (1)
Replicating
Alternating 2-Vector
LCMV, PICV (3)
E6/E7
HPV16+* HNSCC 1L**
Phase 2 Start
H1 2022
HB-300
Replicating
PSA, PSMA PAP (4)
Prostate Cancer
IND Q3 2022
HB-101 (5)
Non-replicating
LCMV
gb/pp65 (6)
CMV
Additional data 2H 2021
Hepatitis B Therapy
Undisclosed
HBV
Advancing toward clinical study
Gilead Investors Biotech
HIV Therapy
Undisclosed
HIV
Advancing toward clinical study
Gilead Investors Biotech
Immuno-Oncology
Infectious Diseases

(1)ClinicalTrials.gov Identifier: NCT04180215; (2)Lymphocytic Choriomeningitis Virus; (3)Pichinde Virus; (4)PSA: Prostate-specific Antigen; PSMA: Prostate-specificMembrane Antigen; PAP: ProstaticAcid Phosphatase;‎(5)ClinicalTrials.gov Identifier: NCT03629080; (6)gB: GlycoproteinB; pp65: Tegument Protein 65. *2L, 2nd Line. **1L, 1st Line.